Načítá se...
Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma
BACKGROUND: Most patients with multiple myeloma (MM) will relapse after an initial response and eventually succumb to their disease. This is due to the persistence of chemotherapy-resistant tumor cells in the patients’ bone marrow (BM) and immunotherapeutic approaches could contribute to eradicating...
Uloženo v:
| Vydáno v: | J Transl Med |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4474344/ https://ncbi.nlm.nih.gov/pubmed/26088750 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-015-0562-5 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|